AGLNYSEServices-Misc Health & Allied Services, NECFiscal year ends December 31
agilon health, inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$88.83+3.71 (+4.36%)
Close on Oct 19, 2026
- Market cap
- $1.53B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-7.8%−3.2 pts over 5 years
Net margin
-6.6%−1.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -2.1% | +35.4% | +37.2% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | – | |
| Return on assets | – | – | -26.0% | |
| Current ratio | – | 1.10 | 1.02 | |
| Debt to equity | – | -0.24 | – | |
| Net debt to EBITDA | – | 1.42× | 0.32× | |
| Interest coverage | – | -7.0× | -69.8× | |
| Capex to revenue | – | 0.1% | 0.2% | |
| Diluted shares | – | 13M | 17M |
Where the cash went
Fiscal 2021 to 2025, five years combined
agilon health generated $598.71M from operations and spent $264.31M on capital expenditure, dividends and share buybacks. 24% of that went back into the business.
Generated
$598.71M
Used
$264.31M
Capital expenditure$64.31M24%Dividends$00%Share buybacks$200.00M76%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4.3%
×Asset turnover3.49×
×Equity multiplier3.07×
=Return on equity, FY2024-45.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -4.3% | 3.49× | 3.07× | -45.9% |
| FY2023 | -6.1% | 2.51× | 2.02× | -30.8% |
| FY2022 | -4.5% | 1.45× | 1.54× | -10.0% |
| FY2021 | -26.7% | 1.50× | 2.52× | -100.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$391.35M
- Cash generatingOperating cash flow above zero-$105.76M
- Return on assets improvedROA up on the prior year-14.9% → -22.6%
- Earnings backed by cashOperating cash flow above net income-$105.76M vs -$391.35M
- Less leverageLong-term debt to assets fell2.0% → 1.2%
- Better liquidityCurrent ratio rose1.27 → 1.02
- No dilutionShare count did not rise16M → 17M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose3.48 → 3.42